Victory Capital Management’s Roivant Sciences ROIV Stock Holding History

Victory Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.22M	Buy	175,883 +4,383	+3%	+$130K	﹤0.01%	1299
2026 Q1	$4.75M	Sell	171,500 -90,384	-35%	-$2.32M	﹤0.01%	1347
2025 Q4	$5.68M	Buy	261,884 +245,886	+1,537%	+$4.85M	﹤0.01%	1257
2025 Q3	$242K	Sell	15,998 -7,311	-31%	-$90.5K	﹤0.01%	2190
2025 Q2	$263K	Sell	23,309 -4,185	-15%	-$45.4K	﹤0.01%	2188
2025 Q1	$277K	Hold	27,494	–	–	﹤0.01%	2154
2024 Q4	$325K	Buy	27,494 +1,588	+6%	+$18.8K	﹤0.01%	2130
2024 Q3	$299K	Sell	25,906 -983	-4%	-$11.2K	﹤0.01%	2137
2024 Q2	$284K	Sell	26,889 -95,141	-78%	-$1.04M	﹤0.01%	2115
2024 Q1	$1.29M	Buy	122,030 +48,207	+65%	+$520K	﹤0.01%	1618
2023 Q4	$829K	Sell	73,823 -788,067	-91%	-$7.68M	﹤0.01%	1800
2023 Q3	$10.1M	Sell	861,890 -328,191	-28%	-$3.71M	0.01%	1013
2023 Q2	$12M	Buy	+1,190,081	New	+$10.6M	0.01%	968

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Victory Capital Management's ROIV Position: Q2 2026 in Review

Victory Capital Management increased its Roivant Sciences (ROIV) stake by 2.6% in Q2 2026, buying an estimated $130K and bringing the position to 175,883 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Victory Capital Management first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. The position peaked at $12M in Q2 2023. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Victory Capital Management held 175,883 shares of Roivant Sciences worth $6.22M as of Q2 2026.
Victory Capital Management bought 4,383 Roivant Sciences shares in Q2 2026, an estimated $130K.
Roivant Sciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1299 holding.
Victory Capital Management first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
Victory Capital Management's Roivant Sciences position peaked at $12M in Q2 2023.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.